Clinical trials have found that the Erzhu jiedu recipe can significantly inhibit the serum AFP and AFP-L3 levels of patients with hepatitis B cirrhosis and hyperalphafetoproteinemia, and has good safety, which is expected to inhibit the occurrence of HCC (Chen et al., 2021). The gene discussed is AFP; the disease is hepatocellular carcinoma.